Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 16/20 | 0.40 |
| ▸ | TAF1 | P21675 | 2/20 | 0.38 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.38 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | BRD1 | O95696 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25898037 | 0.80 | TAF1 (0.38) | TAF1BRPF1BRD4CREBBPCECR2 | |
| SCHEMBL31743137 | 0.77 | MAPT (0.42) | GRM2TAF1BRPF1BRD4CREBBP | |
| SCHEMBL29026946 | 0.76 | BRD4 (0.35) | TAF1BRPF1BRD4CREBBPCECR2 | |
| SCHEMBL31723365 | 0.71 | BRD4 (0.39) | TAF1BRPF1BRD4CREBBPCECR2 | |
| SCHEMBL1047342 | 0.71 | BRD9 (0.39) | GRM2TAF1BRPF1BRD4CREBBP | |
| SCHEMBL582859 | 0.70 | CCNE2 (0.41) | TAF1BRPF1BRD4CREBBPCECR2 | |
| SCHEMBL3577290 | 0.70 | TAF1 (0.41) | TAF1BRPF1BRD4CREBBPCECR2 | |
| SCHEMBL29809118 | 0.70 | CCNE2 (0.41) | TAF1BRPF1BRD4CREBBPCECR2 | |
| SCHEMBL13752828 | 0.70 | BRD4 (0.38) | GRM2TAF1BRPF1BRD4CREBBP | |
| SCHEMBL25899446 | 0.70 | BRD4 (0.38) | TAF1BRPF1BRD4CREBBPCECR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735445-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250042922-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| WO-2025006720-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042922-A1 | KRAS MODULATING COMPOUNDS | KRAS, NRAS, HRAS | GRM2 3644/4885TAF1 1487/4885BRPF1 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.